Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class ASSE: 688266

Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ZG006 Combined with HS-20093 for Injection, Either With or Without Adabepilimab Injection for the Treatment of Extensive-Stage Small Cell Lung Cancer

· Issued by Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ZG006 Combined with HS-20093 for Injection, Either With or Without Adabepilimab Injection for the Treatment of Extensive-Stage Small Cell Lung Cancer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis